Form 4: BioLife Solutions CFO Sells Shares for Tax Obligations

BioLife Solutions' Chief Financial Officer, Troy Wichterman, sold 833 shares of common stock for tax withholding obligations under a pre-arranged trading plan.

Summary

• Troy Wichterman, Chief Financial Officer of BioLife Solutions Inc. (BLFS), reported a sale of common stock.
• The transaction involved the disposition of 833 shares of common stock.
• The shares were sold at a price of $27.36 per share.
• The sale was executed on October 9, 2025.
• Following this transaction, Mr. Wichterman beneficially owns 183,353 shares of common stock.
• The sale was made pursuant to a Rule 10b5-1(c) trading plan, which was adopted on January 3, 2023.
• The purpose of the sale was to satisfy tax withholding obligations related to the vesting of restricted stock.

Sentiment

Score: 5

Explanation: The transaction is a routine insider sale for tax withholding purposes under a pre-arranged 10b5-1 plan, which is generally considered a neutral event and not indicative of management's sentiment towards the company's future prospects.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This insider transaction is a routine disclosure for publicly traded companies and does not provide specific insights into broader industry trends or competitive landscape. It reflects an individual executive's stock activity rather than a company-wide strategic move.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in insider ownership, but its pre-planned, tax-related nature typically mitigates any negative perception. It is unlikely to significantly impact shareholder confidence.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

The reported sale by the Chief Financial Officer is a routine transaction executed under a pre-arranged 10b5-1 trading plan to cover tax withholding obligations. Such sales are common and generally not indicative of a change in the company's fundamentals or management's long-term outlook. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

BioLife Solutions, BLFS, Form 4, Insider Trading, Stock Sale, CFO, Troy Wichterman, Rule 10b5-1, Tax Withholding